Midterm Outcome of Femoral Artery Stenting and Factors Affecting Patency

Overview

Journal Vasc Specialist Int

Date 2016 Jan 1

PMID 26719837

Citations 3

Authors

Jae Seoung Yu

Keun-Myoung Park

Yong Sun Jeon

Soon Gu Cho

Kee Chun Hong

Woo Young Shin

Yun-Mee Choe

Seok-Hwan Shin

Kyung Rae Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to evaluate the early and midterm results of superficial femoral artery (SFA) stenting with self-expanding nitinol stents and to identify the factors affecting patency.

Materials And Methods: SFA stenting was performed in 165 limbs of 117 patients from January 2009 to December 2013. Patients were followed-up for the first occurrence of occlusion or stenosis based on computed tomography and duplex scan results and a decrease in ankle brachial index of >15%.

Results: During the follow-up period (mean, 15.3±3.2 months), no early thrombotic reocclusions occurred within 30 days, but in-stent restenosis developed in 78 limbs. The primary patency rates at 6, 12, 18, and 24 months were 78%, 66%, 42%, and 22%, respectively, and the secondary patency rates were 85%, 72%, 58%, and 58%, respectively. TASC II C or D lesions, stent length >8 cm, number of patent tibial arteries and diabetes were significantly associated with reintervention.

Conclusion: The midterm results of stenting for SFA occlusive disease were disappointing because the primary and secondary patency rates at two years were 22% and 58%, respectively. Reintervention after SFA stenting remains a major problem, particularly in patients with diabetes mellitus or long TASC II C or D lesions.

Citing Articles

First peripheral drug-eluting stent clinical results from China: 1-year outcomes of the Zilver PTX China study.

Ye W, Bohme T, Fu W, Liu C, Zhang X, Liu P Front Cardiovasc Med. 2022; 9:877578.

PMID: 36237908 PMC: 9551216. DOI: 10.3389/fcvm.2022.877578.

Nitinol Self-Expanding Stents for the Treatment of Obstructive Superficial Femoral Artery Disease: Three-Year Results of the RELIABLE Japanese Multicenter Study.

Nakamura M, Jaff M, Settlage R, Kichikawa K Ann Vasc Dis. 2018; 11(3):324-334.

PMID: 30402183 PMC: 6200612. DOI: 10.3400/avd.oa.18-00067.

Major Limb Outcomes Following Lower Extremity Endovascular Revascularization in Patients With and Without Diabetes Mellitus.

Shammas A, Jeon-Slaughter H, Tsai S, Khalili H, Ali M, Xu H J Endovasc Ther. 2017; 24(3):376-382.

PMID: 28440113 PMC: 5624231. DOI: 10.1177/1526602817705135.

References

Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A . Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2014; 131(5):495-502. PMC: 4323569. DOI: 10.1161/CIRCULATIONAHA.114.011004. View

Jens S, Conijn A, Koelemay M, Bipat S, Reekers J . Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (Part 1: Above the knee). Eur J Vasc Endovasc Surg. 2014; 47(5):524-35. DOI: 10.1016/j.ejvs.2014.02.011. View

Pulli R, Dorigo W, Pratesi G, Fargion A, Angiletta D, Pratesi C . Gender-related outcomes in the endovascular treatment of infrainguinal arterial obstructive disease. J Vasc Surg. 2011; 55(1):105-12. DOI: 10.1016/j.jvs.2011.07.050. View

Conrad M, Cambria R, Stone D, Brewster D, Kwolek C, Watkins M . Intermediate results of percutaneous endovascular therapy of femoropopliteal occlusive disease: a contemporary series. J Vasc Surg. 2006; 44(4):762-9. DOI: 10.1016/j.jvs.2006.06.025. View

Hunink M, Donaldson M, Meyerovitz M, Polak J, Whittemore A, Kandarpa K . Risks and benefits of femoropopliteal percutaneous balloon angioplasty. J Vasc Surg. 1993; 17(1):183-92; discussion 192-4. View

Sabeti S, Mlekusch W, Amighi J, Minar E, Schillinger M . Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther. 2005; 12(1):6-12. DOI: 10.1583/04-1359.1. View

Ohki T, Yokoi H, Kichikawa K, Kimura T, Snyder S, Ragheb A . Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials. J Endovasc Ther. 2014; 21(5):644-53. DOI: 10.1583/14-4753.1. View

Werner M, Paetzold A, Banning-Eichenseer U, Scheinert S, Piorkowski M, Ulrich M . Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry. EuroIntervention. 2014; 10(7):861-8. DOI: 10.4244/EIJV10I7A147. View

Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M . The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014; 7(1):10-9. DOI: 10.1016/j.jcin.2013.05.022. View

10.

Stabile E, Virga V, Salemme L, Cioppa A, Ambrosini V, Sorropago G . Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol. 2012; 60(18):1739-42. DOI: 10.1016/j.jacc.2012.07.033. View

11.

Schlager O, Dick P, Sabeti S, Amighi J, Mlekusch W, Minar E . Long-segment SFA stenting--the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther. 2005; 12(6):676-84. DOI: 10.1583/05-1672.1. View